Candriam SCA’s Inovio Pharmaceuticals INO Stock Holding History

Candriam SCA’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-31,668	Closed	-$287K	–	798
2023 Q1	$287K	Buy	+31,668	New	+$540K	﹤0.01%	855
2017 Q4	–	Sell	-5,000	Closed	-$380K	–	762
2017 Q3	$380K	Sell	5,000 -10,000	-67%	-$744K	0.01%	687
2017 Q2	$1.41M	Buy	+15,000	New	+$1.28M	0.03%	524

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Candriam SCA's INO Position: Q2 2023 in Review

Candriam SCA sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 31,668 shares — an estimated $287K sold.

Candriam SCA first reported a position in INO in Q2 2017 and held it in 3 quarters. The position peaked at $1.41M in Q2 2017. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.

Candriam SCA reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 31,668 Inovio Pharmaceuticals shares in Q2 2023, an estimated $287K.
Candriam SCA first reported a position in Inovio Pharmaceuticals in Q2 2017 and held it in 3 quarters.
Candriam SCA's Inovio Pharmaceuticals position peaked at $1.41M in Q2 2017.
133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.